Business
Cytokinetics Announces Five Presentations Related to Aficamten at the European Society of Cardiology Congress 2025
Positive Results from MAPLE-HCM to be Shared in Hot Line Presentation Late Breaking Clinical Science Session to Present Incidence and Impact of Atrial
About this update from Cytokinetics, Incorporated
[{"type":"text","content":"Positive Results from MAPLE-HCM to be Shared in Hot Line Presentation Late Breaking Clinical Science Session to Present Incidence and Impact of Atrial Fibrillation Across Three Clinical Trials of Aficamten in Obstructive Hypertrophic Cardiomyopathy Company to Host Investor Event and Webcast Tuesday September 2, 2025, at 8:00 AM Eastern Time SOUTH SAN FRANCISCO, Calif., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced five presentations related to aficamten at the European Society of Cardiology Congress 2025 taking place in Madrid, Spain from August 29, 2025 – September 1, 2025 including a Hot Line presentation of the primary results from MAPLE-HCM (Metoprolol vs Aficamten in Patients with LVOT Obstruction on Exercise Capacity in HCM) and a Late Breaking Clinical Science presentation relating to the incidence and impact of atrial fibrillation across three clinical trials of aficamten in obstructive hypertrophic cardiomyopathy (HCM). Oral Presentations Title: MAPLE-HCM: Aficamten vs Metoprolol in Obstructive HCMPresenter: Pablo Garcia-Pavia, M.D., Ph.D., Head of the Inherited Cardiac Diseases and Heart Failure Unit, Department of Cardiology, Hospital Universitario Puerta de Hierro and Full Professor, Centro Nacional de Investigaciones Cardiovasculares both in Madrid, SpainDate: August 30, 2025Session Title: Hot Line 2Session Time: 8:15 - 9:45 AM CESTPresentation Time: 9:18 AM CESTLocation: Madrid (Main Auditorium) Title: REDWOOD-HCM, SEQUOIA-HCM and FOREST-HCM Trials: Incidence and Impact of Atrial Fibrillation in Obstructive HCM with AficamtenPresenter: Ahmad Masri, M.D., MS, Director of the Hypertrophic Cardiomyopathy Center at Oregon Health & Science UniversityDate: August 31, 2025Session Title: Late-Breaking Clinical Science: CardiomyopathiesSession Time: 4:15-5:15 PM CESTPresentation Time: 4:45 PM CESTLocation: Budapest (Hall 10) Title: Efficacy and Safety of Long-Term Treatment with Aficamten in Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy: Results from FOREST-HCMPresenter: Sara Saberi, M.D., M.S., Associate Professor of Internal Medicine, University of Michigan Health Frankel Cardiovascular CenterDate: August 31, 2025Session Title: Hypertrophic Cardiomyopathy: From Gene to TreatmentSession Time: 5:00 - 6:20 PM CESTPresentation Time: 5:40 PM CESTLocation: Scienc...